Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-002 COVID-19 booster vaccine in adults
NCT06436911Phase 2Completed
- Sponsor
- Entos Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Covigenix VAX-002 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Entos Pharmaceuticals. Primary endpoints: Safety and Tolerability at 180 days and Immunogenicity Response at 180 days. Started Jul 2024; status: completed.
02
Drugs
Covigenix VAX-002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06436911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436911.